Breaking News Instant updates and real-time market news.

NVS

Novartis

$82.21

-2.18 (-2.58%)

, ABBV

AbbVie

$90.77

-2.32 (-2.49%)

16:44
10/11/18
10/11
16:44
10/11/18
16:44

Novartis division Sandoz, AbbVie resolve IP related litigation for Hyrimoz

Sandoz, a Novartis (NVS) division, announced a global resolution of all intellectual property, or IP, related litigation with AbbVie (ABBV) concerning the proposed Sandoz biosimilar Hyrimoz for reference medicine Humira. Under the terms of the agreement, AbbVie grants Sandoz a non-exclusive license to AbbVie's intellectual property relating to Humira, beginning on certain dates in certain countries in which AbbVie has intellectual property. The license period will begin on October 16 in most countries in the European Union, and on other dates in various other countries outside the U.S. where AbbVie has IP. In the U.S., the license period will begin on September 30, 2023. Sandoz will pay royalties to AbbVie for licensing its Humira patents. All litigation pending between the parties will be dismissed. AbbVie will make no payments to Sandoz. The precise terms are confidential between the parties. Sandoz biosimilar adalimumab was recently approved by the European Commission for the 31 countries of the European economic area, which comprises the 28 member countries of the European Union plus Norway, Iceland and Liechtenstein.

NVS

Novartis

$82.21

-2.18 (-2.58%)

ABBV

AbbVie

$90.77

-2.32 (-2.49%)

  • 19

    Oct

  • 19

    Oct

  • 07

    Nov

NVS Novartis
$82.21

-2.18 (-2.58%)

09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
09/19/18
PIPR
09/19/18
NO CHANGE
Target $50
PIPR
Overweight
Piper recommends Deciphera into systemic mastocytosis data
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Deciphera Pharmaceuticals (DCPH) with a $50 price target following a deep dive into the systemic mastocytosis treatment space and the potential for DCC-2618 to play a meaningful role in the disease. The analyst continues to recommend purchase of Deciphera into the systemic mastocytosis data for DCC-2618 early next year. Given what's been presented before between Novartis' (NVS) midostaurin and Blueprint Medicines' (BPMC) avapritinib, Raymond thinks an overall response rate of greater than 50% with a continued clean safety profile should be considered a win for DCC-2618. He models for DCC-2618 systemic mastocytosis revenue of $44M, $151M, and $290M for 2023 through 2025, respectively. The analyst remains a buyer of Deciphera shares into the Q1 of 2019 data.
09/28/18
WELS
09/28/18
NO CHANGE
WELS
Market Perform
Lilly's migraine treatment approval adds to Teva worries, says Wells Fargo
Wells Fargo analyst David Maris noted that Eli Lilly (LLY) received FDA approval of Emgality for the prevention of migraines and announced a U.S. list price of $6,900 annually, which is in line with Teva's (TEVA) Ajovy and Aimovig from Amgen (AMGN) and Novartis (NVS). Lilly's approval adds to Teva investor worries, said Maris, who sees migraines being a competitive market with similar drugs "where the competitors are marketing powerhouses...and Teva is undergoing a lot of organizational change." He maintains a Market Perform rating on Teva shares.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
Novartis initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Novartis with a Neutral rating and CHF 94 price target, stating that its Alcon spin likely will generate value, but he believes additional pipeline catalysts are needed to drive operating leverage.
ABBV AbbVie
$90.77

-2.32 (-2.49%)

09/19/18
PIPR
09/19/18
NO CHANGE
Target $100
PIPR
Neutral
Piper more worried about AbbVie co-pay accumulator risk than California suit
While shares of AbbVie may move lower today on news of California's insurance regulator suing the company over promotion of Humira, a more fundamental potential drag on Humira remains the advent of co-pay accumulators, Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst sees the California lawsuit as more headline risk than anything but thinks "it may nevertheless serve as a minor overhang on shares." He points out that new research this week by Drug Channels suggests that more than one-third of commercial lives are enrolled in plans that have implemented copay accumulators for 2018, higher than his prior best estimate of 17%. Raymond keeps a Neutral rating on AbbVie with a $100 price target.
09/19/18
FBCO
09/19/18
NO CHANGE
Target $85
FBCO
Underperform
AbbVie's California lawsuit may have broader implications, says Credit Suisse
After the State of California has filed a lawsuit against AbbVie, accusing the company of paying kickbacks to doctors and using a network of nurses to illegally boost Humira prescriptions, Credit Suisse analyst Vamil Divan said he is "not surprised" by the stock's weakness given how leveraged it is to Humira sales and profit, and think there could be additional weakness as the story develops, especially if other states file similar lawsuits against the company. Additionally, he wonders how lawsuits like this may impact marketing practices across the industry. Divan maintains a cautious view on the stock with an Underperform rating and $85 price target, and says he continues to have concerns about the sustainability of Humira given the expected entry of multiple biosimilars in the EU next month expected biosimilar pressure in the U.S. starting in 2023.
09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.

TODAY'S FREE FLY STORIES

22:45
10/15/18
10/15
22:45
10/15/18
22:45
General news
China's CPI grew 2.5% y/y in September »

China's CPI grew…

PYPL

PayPal

$77.22

-1.8 (-2.28%)

20:49
10/15/18
10/15
20:49
10/15/18
20:49
Recommendations
PayPal analyst commentary at Stifel »

PayPal earnings to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 13

    Nov

  • 26

    Nov

ALRM

Alarm.com

$44.50

0.16 (0.36%)

20:45
10/15/18
10/15
20:45
10/15/18
20:45
Upgrade
Alarm.com rating change at First Analysis »

Alarm.com upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

SGBAF

SES S.A.

$0.00

(0.00%)

20:36
10/15/18
10/15
20:36
10/15/18
20:36
Upgrade
SES S.A. rating change at JPMorgan »

SES S.A. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$133.75

-0.03 (-0.02%)

, UNH

UnitedHealth

$259.80

0.36 (0.14%)

20:25
10/15/18
10/15
20:25
10/15/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JNJ

Johnson & Johnson

$133.75

-0.03 (-0.02%)

UNH

UnitedHealth

$259.80

0.36 (0.14%)

GS

Goldman Sachs

$215.28

1.37 (0.64%)

MS

Morgan Stanley

$43.45

(0.00%)

BLK

BlackRock

$427.40

-0.18 (-0.04%)

PLD

Prologis

$63.00

0.45 (0.72%)

PGR

Progressive

$66.23

-0.64 (-0.96%)

GWW

Grainger

$318.38

6.75 (2.17%)

OMC

Omnicom

$69.48

0.8 (1.16%)

CMA

Comerica

$83.69

-1.04 (-1.23%)

JBHT

J.B. Hunt

$111.78

2.52 (2.31%)

DPZ

Domino's Pizza

$273.13

-4.215 (-1.52%)

FHN

First Horizon

$15.99

-0.11 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 24

    Oct

  • 26

    Oct

  • 28

    Oct

  • 05

    Nov

  • 06

    Nov

  • 27

    Nov

  • 24

    Jan

TWLO

Twilio

$76.26

1.27 (1.69%)

, SEND

SendGrid

$30.94

0.04 (0.13%)

20:13
10/15/18
10/15
20:13
10/15/18
20:13
Recommendations
Twilio, SendGrid analyst commentary at MUFG »

MUFG analyst 'fully…

TWLO

Twilio

$76.26

1.27 (1.69%)

SEND

SendGrid

$30.94

0.04 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

PANW

Palo Alto Networks

$209.49

-2.51 (-1.18%)

20:07
10/15/18
10/15
20:07
10/15/18
20:07
Recommendations
Palo Alto Networks analyst commentary at JPMorgan »

Palo Alto Networks'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 10

    Dec

SVA

Sinovac Biotech

$7.16

-0.03 (-0.42%)

20:03
10/15/18
10/15
20:03
10/15/18
20:03
Hot Stocks
Sinovac Biotech commences legal proceedings in Hong Kong »

Senior management of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NWN

Northwest Natural Gas

$67.70

0.36 (0.53%)

20:01
10/15/18
10/15
20:01
10/15/18
20:01
Hot Stocks
Northwest Natural Water unit to buy Sunriver Water LLC, terms not stated »

NW Natural Water Company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VFC

VF Corp.

$87.65

0.11 (0.13%)

19:53
10/15/18
10/15
19:53
10/15/18
19:53
Initiation
VF Corp. initiated at Wedbush »

VF Corp. initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

LVS

Las Vegas Sands

$55.84

-0.32 (-0.57%)

19:39
10/15/18
10/15
19:39
10/15/18
19:39
Upgrade
Las Vegas Sands rating change at HSBC »

Las Vegas Sands upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OXY

Occidental Petroleum

$72.24

-4.69 (-6.10%)

19:37
10/15/18
10/15
19:37
10/15/18
19:37
Recommendations
Occidental Petroleum analyst commentary at MUFG »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

AVMXY

Avita Medical

$0.00

(0.00%)

19:24
10/15/18
10/15
19:24
10/15/18
19:24
Hot Stocks
Avita Medical announces Recell trial results presentation »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.56

-0.2 (-0.13%)

19:16
10/15/18
10/15
19:16
10/15/18
19:16
Hot Stocks
Facebook confirms expanding policies on voter suppression »

Facebook said in a blog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

JBHT

J.B. Hunt

$111.78

2.52 (2.31%)

, SEND

SendGrid

$30.94

0.04 (0.13%)

18:58
10/15/18
10/15
18:58
10/15/18
18:58
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: J.B.…

JBHT

J.B. Hunt

$111.78

2.52 (2.31%)

SEND

SendGrid

$30.94

0.04 (0.13%)

TWLO

Twilio

$76.26

1.27 (1.69%)

HQCL

Hanwah Q Cells

$8.20

-0.13 (-1.56%)

ADBE

Adobe

$238.05

-10.84 (-4.36%)

CRY

CryoLife

$30.64

0.42 (1.39%)

TRQ

Turquoise Hill

$1.96

-0.015 (-0.76%)

JELD

Jeld-Wen

$21.31

-0.04 (-0.19%)

TTOO

T2 Biosystems

$5.30

0.17 (3.31%)

ACRS

Aclaris Therapeutics

$13.38

-0.21 (-1.55%)

AGN

Allergan

$183.03

-0.275 (-0.15%)

PANW

Palo Alto Networks

$209.49

-2.51 (-1.18%)

SNAP

Snap

$7.41

0.225 (3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

  • 25

    Oct

  • 30

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 27

    Nov

  • 10

    Dec

SHLD

Sears

$0.31

-0.0901 (-22.52%)

18:43
10/15/18
10/15
18:43
10/15/18
18:43
Hot Stocks
Sears receives court approval of 'first day' motions to support business ops »

Sears Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAB

Wabtec

$97.03

1.63 (1.71%)

18:38
10/15/18
10/15
18:38
10/15/18
18:38
Upgrade
Wabtec rating change at Wellington Shields »

Wabtec upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 14

    Nov

TGE

Tallgrass Energy

$23.73

0.17 (0.72%)

18:30
10/15/18
10/15
18:30
10/15/18
18:30
Hot Stocks
Tallgrass Energy, Silver Creek Midstream to expand Powder River Basin JV »

Tallgrass Energy and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$113.47

0.86 (0.76%)

, GOOG

Alphabet

$1,092.00

-18.93 (-1.70%)

18:21
10/15/18
10/15
18:21
10/15/18
18:21
Hot Stocks
Disney-backed Jaunt to focus efforts on AR, says some staff will be 'moving on' »

Jaunt, a top-funded VR…

DIS

Disney

$113.47

0.86 (0.76%)

GOOG

Alphabet

$1,092.00

-18.93 (-1.70%)

GOOGL

Alphabet Class A

$1,101.58

-19.41 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 08

    Nov

  • 03

    Mar

HMC

Honda

$27.05

-0.16 (-0.59%)

18:19
10/15/18
10/15
18:19
10/15/18
18:19
Hot Stocks
Honda to recall 54 model year 2017-2018 Honda Civic and Honda CR-V vehicles »

American Honda will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

MSFT

Microsoft

$107.60

-1.94 (-1.77%)

18:15
10/15/18
10/15
18:15
10/15/18
18:15
Hot Stocks
Microsoft co-founder Paul Allen dead at 65 »

Vulcan Inc. released…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 13

    Nov

  • 28

    Nov

  • 03

    Mar

OII

Oceaneering

$25.69

0.4 (1.58%)

18:15
10/15/18
10/15
18:15
10/15/18
18:15
Hot Stocks
Oceaneering provides update following Hurricane Michael »

Oceaneering International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

JOE

Saint Joe Co.

$15.28

0.01 (0.07%)

18:07
10/15/18
10/15
18:07
10/15/18
18:07
Hot Stocks
Saint Joe released additional information regarding Hurricane Michael »

The St. Joe Company …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBR

Petrobras

$15.41

0.055 (0.36%)

18:05
10/15/18
10/15
18:05
10/15/18
18:05
Periodicals
Petrobras anticipates reviving TAG sale over next month, Reuters says »

Petrobras expects to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$238.05

-10.84 (-4.36%)

18:02
10/15/18
10/15
18:02
10/15/18
18:02
Hot Stocks
Adobe says it sees increased demand for PDF capabilities »

Says it has over 300,000…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.